A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With Relapsed / Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs AMG-562 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 19 Jun 2019 Planned primary completion date changed from 16 Aug 2021 to 30 Aug 2021.
- 03 Apr 2019 Planned End Date changed from 30 Dec 2021 to 16 Aug 2023.
- 03 Apr 2019 Planned primary completion date changed from 30 Dec 2021 to 16 Aug 2021.